Catalent still in strategic acquisition mode after a slew of big deals
- Catalent, a New Jersey-based contract development and manufacturing organization, plans to continue its focus on strategic acquisitions in 2016, although the potential size of a target is unclear, reports in-Pharmatechnologist. The company has completed nine acquisitions since 2012, with a total value of about $700 million.
- In terms of acquisition strategy, Catalent sees growth potential in delivery technologies and specialized logistics.
- Catalent has been active globally, closing deals and acquisitions across the U.S., China, and Brazil, among others. Catalent has two facilities in China, and three in Brazil.
Beneath the din of an increasingly productive biopharma R&D sector, companies in the contract manufacturing and pharma services industry are working to keep up. The demand for clinical trials is rising, meaning companies like Catalent are responding to demand.
Catalent's strategy is to continue pursuing strategic acquisitions, with a distinct focus on technologies that improve both solubility and bioavailability, according to Elliot Berger, marketing and strategy VP, in remarks to in-Pharmatechnologist.
While Catalent clearly plans to continue to make acquisitions in key territories, the company has not revealed its ideal target size.
- in-Pharma Technologist Catalent continues to scout acquisitions and licensing in 2016